Olema Oncology

512 2nd St., 4th Floor
San Francisco
California
94107
United States

About Olema Oncology

We exist to develop therapies that offer the potential to improve outcomes for women living with cancer. We approach these goals with a single-minded focus.

At Olema Oncology, we leverage our deep understanding of endocrine-driven cancers, nuclear receptors and mechanisms of acquired resistance with the goal of transforming the standard of care for women living with cancer by focusing on developing more convenient and effective therapies. Join us as we aim to design therapies for improving lives.

Why Join Us?

We believe that great ideas and discoveries come from a mix of expertise, background, and experience. Olema is building a culture where the value of difference is celebrated. We provide equal opportunity to all employees and applicants for employment and offer competitive compensation and benefits.

Olema seeks to provide an open, flexible, and friendly work environment to empower people and to provide them with a platform to develop their long-term careers.

Located in Cambridge, MA and San Francisco, CA

50 articles with Olema Oncology

Olema Oncology Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Strategic Update

3/9/2023

Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today reported financial results for the fourth quarter and full-year ended December 31, 2022, and provided a strategic update.
Olema Oncology to Present at Oppenheimer 33rd Annual Healthcare Conference

3/2/2023

Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that Sean Bohen, M.D., Ph.D., President and Chief Executive Officer, will present at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15, 2023, at 2:40 p.m. ET.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 02, 2023

3/2/2023

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, announced that the Company granted stock options to three new employees to purchase an aggregate of 42,300 shares of the Company's common stock, effective as of March 1, 2023.
Olema Oncology to Participate at Upcoming Investor Conferences - February 21, 2023

2/21/2023

Olema Pharmaceuticals, Inc. announced that the Company will present at the following upcoming investor conferences:
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 02, 2023

2/2/2023

Olema Pharmaceuticals, Inc. announced that the Company granted stock options to four new employees to purchase an aggregate of 97,200 shares of the Company's common stock, effective as of February 1, 2023.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 04, 2023

1/4/2023

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, announced that the Company granted stock options to three new employees to purchase an aggregate of 54,400 shares of the Company's common stock, effective as of January 3, 2023.
Olema Oncology to Present at 41st Annual J.P. Morgan Healthcare Conference

1/3/2023

Olema Pharmaceuticals, Inc. announced that Sean Bohen, M.D., President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Wednesday, January 11, 2023, at 2:15 p.m. PT.
Olema Oncology Announces OP-1250 Demonstrates Attractive Combinability with CDK 4/6 Inhibitor Palbociclib in Phase 1b Dose Escalation Study

12/7/2022

Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, or the “Company”, Nasdaq: OLMA) today announced results from a Phase 1b dose escalation clinical study of OP-1250, the Company’s complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD), in combination with palbociclib, a CDK 4/6 inhibitor for the treatment of metastatic ER+/HER2- breast cancer.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 02, 2022

12/2/2022

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, announced that the Company granted stock options to two new employees to purchase an aggregate of 62,800 shares of the Company's common stock, effective as of December 1, 2022.
Olema Oncology Announces Poster Presentations at the 2022 San Antonio Breast Cancer Symposium (SABCS)

11/21/2022

Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) today announced two poster presentations on OP-1250, the Company’s complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in development for the treatment of metastatic breast cancer, at the upcoming San Antonio Breast Cancer Symposium (SABCS) meeting being held December 6-10, 2022, at the Henry B. Gonzalez Convention Center in San Antonio, Texas.
Olema Oncology Reports Third Quarter 2022 Financial Results and Provides Corporate Update

11/8/2022

Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today reported third quarter financial results for the period ended September 30, 2022, and provided a business update.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 02, 2022

11/2/2022

Olema Pharmaceuticals, Inc. announced that the Company granted stock options to two new employees to purchase an aggregate of 40,400 shares of the Company's common stock, effective as of November 1, 2022.
Olema Oncology to Present at Upcoming Investor Conferences in November

11/1/2022

Olema Pharmaceuticals, Inc. today announced that the Company will present at the following investor conferences in November.
Olema Oncology Announces Complete ER Antagonist OP-1250 Continues to Demonstrate Robust Activity in Phase 1/2 Clinical Trial

10/26/2022

Olema Pharmaceuticals, Inc. announced preliminary clinical results from a Phase 1/2 clinical study of OP-1250, the Company’s complete estrogen receptor antagonist and selective ER degrader in development for the treatment of metastatic breast cancer.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 04, 2022

10/4/2022

Olema Pharmaceuticals, Inc. announced that the Company granted stock options to four new employees to purchase an aggregate of 58,300 shares of the Company's common stock, effective as of October 3, 2022.
Olema Oncology to Present at H.C. Wainwright 24th Annual Global Investment Conference

9/6/2022

Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that Shane Kovacs, Chief Operating and Financial Officer, will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 01, 2022

9/1/2022

Olema Pharmaceuticals, Inc. announced that the Company granted stock options to three new employees to purchase an aggregate of 72,200 shares of the Company's common stock, effective as of September 1, 2022.
Olema Oncology Reports Second Quarter 2022 Financial Results and Provides Corporate Update

8/9/2022

Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today reported second quarter financial results for the period ended June 30, 2022, and provided a business update.
Olema Oncology Advances OP-1250 into Phase 2 Monotherapy Expansion in Patients with ER+/HER2- Advanced Breast Cancer

8/9/2022

Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), today announced the advancement of OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), into Phase 2 clinical development for the treatment of ER+/HER2- metastatic breast cancer.
Olema Oncology to Present at Canaccord Genuity 42nd Annual Growth Conference

8/4/2022

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022 at 1:30 p.m. ET.